Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...
Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...
Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications ...
Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...
As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...
VRBPAC voted 9-0 in both adults 50–64 and ≥65 years that mRNA-1010’s benefit–risk profile is favorable, despite FDA staff noting evidence gaps in select subpopulations. Phase III efficacy data showed ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...
Total deal value climbed to $135.7 billion for the full year in 2025, according to China's National Medical Products ...
Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...
Pharmaceutical Executive spoke with Lisa Bollinger, chief medical officer at Polaryx. The clinical-stage biotech focuses on ...
In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results